Last reviewed 2026-04-23 · How we verify

The Clopidogrel

Clopidogrel inhibits platelet activation and aggregation by irreversibly inhibiting the P2Y12 receptor.

Clopidogrel inhibits platelet activation and aggregation by irreversibly inhibiting the P2Y12 receptor. Used for Acute coronary syndrome, Myocardial infarction, Stroke prevention in atrial fibrillation.

At a glance

Mechanism of action

This is achieved through the irreversible binding of clopidogrel to the P2Y12 receptor on platelet surfaces, preventing adenosine diphosphate (ADP) from binding and activating the receptor. As a result, platelet activation and aggregation are reduced, which in turn reduces the risk of thrombotic events such as myocardial infarction and stroke.

Approved indications

• Acute coronary syndrome
• Myocardial infarction
• Stroke prevention in atrial fibrillation

Common side effects

• Bleeding
• Thrombocytopenia
• Neutropenia

Key clinical trials

• The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
• Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
• Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
• PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
• SIMPLAAFY Clinical Trial (NA)
• INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT) (NA)
• STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant (PHASE4)
• Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.